Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal
publication date: May 17, 2022
Shanghai Henlius Biotech signed a $55 million agreement to out-license rights for three biosimilar drugs in 16 Latin America countries to Eurofarma, a Brazil pharma. Eurofarma will have rights to market the three biosimilars to drugs that were originally developed by Genentech: Rituxan (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab). Previously, Henlius had out-licensed rights to some of the drugs in other South American countries, as it has for major markets around the world. Henlius develops biosimilars, bio-betters and novel biologic candidates. More details....
Stock Symbol: (HK: 2696)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.